Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-sense oligo
Biotech
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of phase 3 studies, setting up the pharma for a push to the FDA.
James Waldron
Jan 7, 2026 6:15am
GSK pays $17.5M for CAMP4 regulatory RNA deal
Dec 18, 2025 7:00am
Lilly pens $13M upfront oligonucleotide AI pact with Creyon Bio
Apr 29, 2025 10:07am
After 11-month romance, GSK buys oligonucleotide partner Elsie
Jun 6, 2024 9:41am
Creyon collects $40M to create 'on demand' RNA-based medicines
Mar 8, 2022 10:00am
BMS, VCs back Ceptur with $75M for RNA meds to silence pre-mRNA
Jan 19, 2022 7:00am
